Yamaguchi K相关文献与解析，生知库 | 链接生命科学的每一步

日期影响因子

Preclinical identification and clinical validation of dynamic biomarkers for trifluridine/tipiracil with or without bevacizumab in metastatic colorectal cancer

在转移性结直肠癌中，对三氟尿苷/替吡嘧啶联合或不联合贝伐珠单抗的动态生物标志物进行临床前鉴定和临床验证

doi:10.1016/j.esmogo.2026.100323

Suenaga, M; Mashima, T; Kawata, N; Dan, S; Seimiya, H; Yamaguchi, K

发表日期：2026

文献求助收藏

Semiquantitative CLDN18 expression and clinical outcomes in patients with CLDN18-positive gastric cancer treated with zolbetuximab plus chemotherapy

半定量CLDN18表达与接受佐贝妥昔单抗联合化疗治疗的CLDN18阳性胃癌患者的临床结局

doi:10.1016/j.esmogo.2026.100304

Ooki, A; Nakano, K; Shimozaki, K; Takamatsu, M; Fukuoka, S; Sakata, S; Osumi, H; Yoshikawa, K; Toyokawa, E; Yoshino, K; Udagawa, S; Wakatsuki, T; Ogura, M; Shinozaki, E; Chin, K; Kawachi, H; Yamaguchi, K

发表日期：2026

文献求助收藏

BevRam-GC01 study protocol: a phase I trial of bevacizumab plus ramucirumab and paclitaxel in advanced gastric cancer

BevRam-GC01 研究方案：贝伐珠单抗联合雷莫芦单抗和紫杉醇治疗晚期胃癌的 I 期临床试验

doi:10.1016/j.esmogo.2025.100299

Wakatsuki, T; Mashima, T; Miyazaki, N; Osumi, H; Fukuoka, S; Ooki, A; Shimozaki, K; Ogura, M; Yoshino, K; Udagawa, S; Shinozaki, E; Chin, K; Ishida, N; Seimiya, H; Yamaguchi, K

发表日期：2026

文献求助收藏

Efficacy of pembrolizumab in microsatellite-stable, tumor mutational burden-high metastatic colorectal cancer: genomic signatures and clinical outcomes

帕博利珠单抗治疗微卫星稳定型、肿瘤突变负荷高转移性结直肠癌的疗效：基因组特征和临床结果

期刊:ESMO Open

影响因子:8.3

doi:10.1016/j.esmoop.2024.104108

Yamaguchi, K; Tsuchihashi, K; Ueno, S; Uehara, K; Taguchi, R; Ito, M; Isobe, T; Imajima, T; Kitazono, T; Tanoue, K; Ohmura, H; Akashi, K; Baba, E

发表日期：2025

文献求助收藏

Phase I study of H3B-6545 in patients with estrogen receptor-positive breast cancer

H3B-6545治疗雌激素受体阳性乳腺癌患者的I期研究

期刊:ESMO Open

影响因子:8.3

doi:10.1016/j.esmoop.2025.105290

Yonemori, K; Shimoi, T; Yamamoto, K; Kogawa, T; Kitano, S; Kobayashi, S; Yanai, K; Yamaguchi, K; Otake, Y; Hojo, S; Ono, M

免疫/内分泌

发表日期：2025

文献求助收藏

The clinical utility of an mGPS and SII combined score in patients with advanced gastric cancer treated with nivolumab monotherapy

mGPS 和 SII 联合评分在接受纳武利尤单抗单药治疗的晚期胃癌患者中的临床应用价值

doi:10.1016/j.esmogo.2025.100177

Udagawa, S; Ooki, A; Osumi, H; Yoshino, K; Tamba, M; Shimozaki, K; Fukuoka, S; Wakatsuki, T; Ogura, M; Shinozaki, E; Chin, K; Yamaguchi, K

发表日期：2025

文献求助收藏

Prognostic factors and treatment response in HER2-positive gastric cancer patients receiving trastuzumab deruxtecan: secondary analysis of the EN-DEAVOR study

接受曲妥珠单抗德鲁替康治疗的HER2阳性胃癌患者的预后因素和治疗反应：EN-DEAVOR研究的二次分析

doi:10.1016/j.esmogo.2025.100184

Nakanishi, K; Sugimoto, N; Kodera, Y; Kawakami, H; Makiyama, A; Konishi, H; Morita, S; Narita, Y; Minashi, K; Imano, M; Inamoto, R; Nishina, T; Kawakami, T; Hagiwara, M; Kume, H; Yamaguchi, K; Hashimoto, W; Muro, K

发表日期：2025

文献求助收藏

Real-world clinical impact of first-line immune checkpoint inhibitor-based therapy in advanced esophageal squamous cell carcinoma

一线免疫检查点抑制剂疗法在晚期食管鳞状细胞癌中的真实临床影响

doi:10.1016/j.esmogo.2025.100171

Tamba, M; Chin, K; Osumi, H; Ogura, M; Fukuoka, S; Udagawa, S; Shimozaki, K; Yoshino, K; Wakatsuki, T; Shinozaki, E; Yamaguchi, K; Ooki, A

细胞生物学

免疫/内分泌

发表日期：2025

文献求助收藏

Clinical efficacy of nivolumab-based therapy for HER2-negative diffuse-type advanced gastric or gastroesophageal junction adenocarcinoma with peritoneal dissemination

纳武利尤单抗治疗伴有腹膜播散的HER2阴性弥漫型晚期胃癌或胃食管交界处腺癌的临床疗效

doi:10.1016/j.esmogo.2025.100143

Suzuki, Y; Shimozaki, K; Udagawa, S; Chin, K; Osumi, H; Fukuoka, S; Yoshino, K; Tamba, M; Wakatsuki, T; Ogura, M; Shinozaki, E; Yamaguchi, K; Ooki, A

发表日期：2025

文献求助收藏

Managing zolbetuximab-induced nausea and vomiting: a proposal for a pragmatic approach in clinical practice

佐贝妥昔单抗引起的恶心和呕吐的管理：临床实践中一种务实的治疗方法

doi:10.1016/j.esmogo.2024.100128

Shimozaki, K; Ooki, A; Yamahata, Y; Aoyama, T; Yoshino, K; Tamba, M; Udagawa, S; Fukuoka, S; Osumi, H; Wakatsuki, T; Shinozaki, E; Ogura, M; Chin, K; Yamaguchi, K

发表日期：2025

文献求助收藏